Location:eURO Auditorium (Hall C1, Level 0)
This session will address challenging clinical scenarios and treatment decisions that urologists have to deal with in daily practice. Whilst there are high quality EAU Guidelines that give generic guidance, this session will highlight how to use evidence and guidelines on the one hand and highlight the importance of tailoring care to the needs of each individual patient on the other, including when it is appropriate to deviate from the EAU Guidelines.
Institutes: 1Telesta Therapeutics, Inc, Department, Pointe Claire, Canada, 2The University of Texas M.D. Anderson Cancer Center, Dept. of Urology, Houston, United States of America, 3McDougall Scientific Ltd, Department, Toronto, Canada
To present results of MCNA in patients with BCG Unresponsive NMIBC showing how in this highest risk subgroup of BCG Failures MCNA achieves 1 year DFS of 35% for overall population; 24% for CIS; and 60% for papillary tumors.